/

Omeros Corporation

OMER US

OMER USOmeros Corporation

United States Composite

3.04

USD

-0.05

(-1.62%)

0.32EPS Dil.

9.55P/E

191.11MMarket Cap

Next Earnings

March 25

Held by Insiders

4.04%

Held by Institutions

39.86%

Short % of Float

21.99%

YTD Yield

-36.85%

3Y Yield

-80.43%

5Y Yield

-80.56%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

100

LT Borrowings

221

222

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

292

342

184

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

417

389

351

Cash, Cash Equivalents & STI

371

341

310

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

139

144

147

Payables & Accruals

ST Debt

100

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

Net Income, GAAP

-54.65%

-97.28%

-75.77%

Free Cash Flow

-23.68%

-38.91%

20.91%

Total Cash Common Dividend

- -

Total Equity

-332.18%

-622.97%

258.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

-80

- -

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.57

-0.46

-0.36

4.48

3.12

2022

-0.53

-0.49

-0.28

2.05

0.76

2023

-0.54

-0.59

-0.60

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Gregory A. Demopulos M.D.
Full Time Employees: 196
Sector: Healthcare
Industry: Biotechnology
Address: The Omeros Building Seattle WA United States 98119
Website: www.omeros.com
Business: Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Company News

Tipranks
16 days ago
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Yahoo
23 days ago
Q4 2023 Omeros Corp Earnings Call
Yahoo
23 days ago
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript
Yahoo
23 days ago
Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results
Yahoo
24 days ago
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Yahoo
a month ago
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Yahoo
a month ago
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade

Company Description

CEO: Dr. Gregory A. Demopulos M.D.
Full Time Employees: 196
Sector: Healthcare
Industry: Biotechnology
Address: The Omeros Building Seattle WA United States 98119
Website: www.omeros.com
Business: Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Company News

Tipranks
16 days ago
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Yahoo
23 days ago
Q4 2023 Omeros Corp Earnings Call
Yahoo
23 days ago
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript
Yahoo
23 days ago
Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results
Yahoo
24 days ago
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
Yahoo
a month ago
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
Yahoo
a month ago
Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade